Magnikor

Magnikor is an antithrombotic effect with combinatorial properties, the active ingredients of which are acetylsalicylic acid and magnesium hydroxide. 

[1]

Indications Magnikor

  Indications for the use of the medicine Magnikor are as follows:

• Magnikor is recommended for acute ischemic heart disease, unstable angina, acute myocardial infarction.
• The use of a drug for chronic ischemic heart disease is shown.
• This medication is used in the primary prevention of thrombosis.
• The drug is used to prevent the occurrence of thrombi after the initial treatment.
• Magnikor is recommended for the primary prevention of cardiovascular diseases, for example, acute coronary syndrome in patients who are at risk of developing cardiovascular diseases with provoking factors, namely:
• arterial hypertension,
• diabetes mellitus,
• obesity with body mass index <30,
• hypercholesterolemia,
• with a previous myocardial infarction in patients under the age of fifty-five years.

Release form

 Composition:

• active components - each tablet consists of 75 mg of acetylsalicylic acid and 15.2 mg of magnesium hydroxide;
• of the excipients there is a content of a certain amount of corn starch, microcrystalline cellulose, potato starch, magnesium stearate, Opadry II White film coating mixture consisting of hydroxypropylmethyl cellulose, lactose monohydrate, polyethylene glycol, titanium dioxide (E 171), triacetin.   

Form of release of the medicine:

• in round tablets, convex on both sides, covered with a shell, similar to a film of white or close to white;
• The tablets are packed in blisters of ten;
• each package contains three or ten blisters. 

[2]

Pharmacodynamics

    Pharmacodynamics of Magnikor drug is as follows:

1. Acetylsalicylic acid, which is present in the drug, has an anti-inflammatory, antipyretic, analgesic and anti-aggregative effect. The basic result of this component of the drug is a slowdown in the production of prostaglandins and thromboxanes. The parallel effect of analgesia is a slowing down of the processes of production of cyclooxygenase. The anti-inflammatory effect is achieved by slowing the synthesis of PGE2, thereby lowering the rate of blood flow.
2. Due to the action of acetylsalicylic acid suppression of the irreversible nature of prostaglandin synthesis of G / H classes occurs. Such an effect on these substances does not stop even when the acetylsalicylic acid is completely eliminated from the body. This is a consequence of the effect of acetylsalicylic acid on the synthesis of thromboxanes, which are in platelets. The clinical picture of this effect shows an increase in the bleeding time. Normalization of bleeding occurs with the passage of time, after the formation of new platelets.
3. The magnesium hydroxide present in the medicament acts as an antacid component and as a protective substance of the epithelium of the stomach and intestines from the aggressive action of acetylsalicylic acid.

Pharmacokinetics

The pharmacokinetics of Magnikor is as follows:

• After taking the drug orally, the active ingredients of the medication immediately enter the bloodstream through the mucosa of the gastrointestinal tract. If you take Magnikor after eating, then the rate of absorption decreases. Reduced absorption of the active components of the drug occurs in patients who are susceptible to migraines. The best absorption of the drug is seen in patients with achalogia or in patients who constantly use antacid medicines and polysorbent drugs.
• The maximum content of active substances in the serum is about one and a half or two hours after taking Magnikor.
• Magnesium hydroxide with low speed and small doses is absorbed into the mucosa of the small intestine.
• The binding of acetylsalicylic acid to serum proteins is 80 to 90 percent. The proportion of the weight distribution of the active components of Magnikor in adult patients is 170 ml per 1 kg of body weight. Salicylates have the feature of rapid binding to proteins and rapid transport to all organs and systems. Acetylsalicylic acid perfectly penetrates the placental and blood-brain barrier, appears in breast milk during lactation in a significant amount.
• The binding of magnesium to serum proteins is worse (approximately 25 to 30 percent). In this form, it is transported throughout the body and is able to penetrate the placental barrier. Some magnesium appears in breast milk during the lactation period.
• The transformation of acetylsalicylic acid in the epithelium of the stomach occurs to its most active component, salicylate. When absorbed through the mucous membranes, acetylsalicylic acid changes at a high rate to salicylic acid. Although in the first twenty minutes after ingestion Magnikor still in the blood plasma prevails active component in an unchanged form.
• Salicylate changes to the final products of transformation in the liver. The average half-life of the drug is between two and three hours. If Magnikor was taken in a large dose, the half-life is increased to 24 - 30 hours. Non-transformed salicylates are excreted in the urine, and the level of acidity of urine affects the amount of excretion of the substance. With acidic retraction, about two percent of salicylates are excreted, and in alkaline solutions, up to thirty percent.
• A part of magnesium is excreted from the body by means of urine, and the other part of the substance is absorbed repeatedly and is removed with feces.
   

Dosing and administration

   The method of application and dose Magnilek are as follows:

1. Beforehand, before starting reception of Magnikor, one must necessarily consult with a specialist who will prescribe the duration of the course of treatment and the daily amount of the medicine based on the clinical picture of the disease.
2. Tablets are swallowed as a whole. Sometimes, for convenience, the tablet is divided into two parts, chewed or pre-rubbed.
3. In acute or chronic ischemic heart disease, treatment with a daily amount of 150 mg should be started. The supporting daily amount of medication for these ailments is 75 mg.
4. In acute myocardial infarction, unstable angina, it is recommended to begin treatment with a daily amount of medication in 150 - 450 mg. Use of the drug should begin immediately after the discovery of the first symptoms of disease. 
5. In the prevention of repeated thrombosis, the initial daily amount of the drug is 150 mg; maintaining a daily quantity of 75 mg.
6. For the purpose of initial preventive use in the formation of thrombi, a daily amount of a drug is considered to be 150 mg.
7. In the initial prevention of cardiovascular diseases (eg, acute coronary syndrome) in those patients who have the prerequisites for the onset of cardiovascular disease, the amount of medication per day is 75 mg.

[4]

Use Magnikor during pregnancy

 Use Magnikor during pregnancy is possible only after consulting a specialist.

If the positive result for the mother's organism from the use of the medicine exceeds the risk of developing a fetus, the medication is prescribed for use in the first and second trimesters of pregnancy (from the first to the sixth month). In this case, Magnikor is used only in the smallest amounts - up to 100 mg per 1 kg of body weight with constant monitoring by a specialist.

In the third trimester of pregnancy Magnikor can not be used.

Contraindications

Contraindications to the use of Magnikor following, can not be used when:

• Hypersensitivity to the components of the drug (salicylic acid and its derivatives).
• The ulcer of the stomach at the time of the acute form of the disease.
• Greater probability of bleeding (with a lack of vitamin K, anemia, thrombocytopenia).
• Heavy liver failure.
• Severe dysfunction of renal activity (with a glomerular filtration rate of less than ten mL per minute).
• Explicit manifestations of heart failure.
• Asthma or edema Quincke, which occurred as a result of taking non-steroid medications with anti-inflammatory action or using salicylates in the treatment of diseases.
• Third trimester of pregnancy and lactation.
• The age period is up to 12 years.

Side effects Magnikor

Side effects of the drug Magnikor are divided into groups as follows:

1. Very common (more than one case out of ten).
2. Distributed (more than one case in a hundred, less than one in ten cases).
3. Undistributed (more than one case out of a thousand, less than one in a hundred cases).
4. Rarely occurring (more than one case out of ten thousand, less than one in a thousand cases).
5. Very rarely common (less than one case out of ten thousand), taking into account individual manifestations.

Side effects of the drug Magnorcore:

Concerning the circulatory and lymphatic system -

• very common - the appearance of severe bleeding, slowing the pooling of platelets;
• uncontrolled - the appearance of bleeding latent form;
• rarely common - the occurrence of anemia (with prolonged use of the drug);
• very rarely common - the appearance of hypothrombinemia (due to the use of large doses of the drug), thrombocytopenia, neutropenia, agranulocytosis, aplastic anemia, eosinophilia.

Touching the central nervous system -

• common - the appearance of migraines, insomnia;
• unrestricted - the appearance of vertigo (vertigo), drowsiness, sleep disorders, ringing in the ears;
• rarely widespread - the emergence of intracerebral hemorrhages, changes in severity of hearing reversible character and deafness (with the maximum amounts of drug use).

Concerning the respiratory system -

• common - the appearance of bronchospasm (in asthmatic patients).

Concerning the digestive system - 

• very common - the appearance of heartburn, reflux;

• widespread - the appearance of erosive lesions of the upper part of the digestive tract, nausea, dyspepsia, vomiting, diarrhea;
• uncomplicated - the appearance of ulcers of the upper part of the digestive tract, including vomiting with blood and deglotepodobnogo bowel movement;
• rarely common - the occurrence of gastrointestinal bleeding, perforations;

• very rarely common - the appearance of stomatitis, esophagitis, toxic lesions with ulcers of the lower gastrointestinal tract, strictures, colitis, exacerbations of the syndrome of irritation of the large intestine.

Touching the liver -

• rarely common - increased levels of transaminase and alkaline phosphatases of blood plasma;

• very rare - the emergence of dose-dependent hepatitis of the average severity level in an acute form, which is reversible, the cause of which is the excess of several times the necessary doses of the drug.

Concerning skin and immunity -

• common - the appearance of urticaria, rashes of a different nature, angioedema, hemorrhagic vasculitis, purpura, erythema multiforme, Lyell syndrome, Stevens-Johnson syndrome;
• unresolved - the emergence of anaphylactic reactions, allergic rhinitis.

Concerning the endocrine system -

• rarely common - the appearance of hypoglycemia.

[3]

Overdose

   An overdose of the drug Magnilek is manifested in the following:

1. A dangerous amount of medicine, which may cause symptoms of overdose, is a daily amount of medication for adults more than 150 mg per kg of body weight of the patient.
2. Due to the long-term use of large amounts of the drug (over 150 mg per day), there are signs of chronic moderate poisoning. Sometimes there is dizziness and headache, confusion of deafness, noise in the ears, vessels widen, sweating, nausea, vomiting.
3. Severe stage of drug poisoning provokes the appearance of the following symptoms: unexpectedly arisen anxiety, excessive pulmonary ventilation, alkaloid alkalosis, a strong rise in body temperature, ketosis, metabolic acidosis. In case of severe poisoning with the drug, the central nervous system is depressed, which can provoke a coma, cardiovascular collapse and respiratory arrest.
4. In acute poisoning with salicylates, there are often symptoms of acute liver failure (with a daily intake of more than 300 mg per kg of body weight).
5. The lethal amount of the drug is the intake of more than 500 mg per 1 kg of body weight.
6. Treatment of overdose: in case of acute overdosage, rinse the stomach immediately and then use activated charcoal. It is necessary to restore the water-electrolyte balance to prevent the occurrence of acidosis, a critical loss of fluid in the body, hyperpyrexia and hyperkalemia. Sometimes it is necessary to use the following effective methods of sorting toxins from blood serum - hemodialysis, hemoperfusion and alkaline diuresis.

Interactions with other drugs

   The interaction of Magnikor with other drugs is as follows:

1. With parallel use Magnikor increases the effectiveness of anticoagulants - warfarin, heparin, clopidogrel, fenprokumona and hypoglycemic drugs.
2. Magnikor has the ability to suppress the diuretic effect of furosemide, as well as spinolactone, ATP inhibitors.
3. Do not use Magnikor with non-steroidal anti-inflammatory drugs. Antacid preparations decrease the absorption of the above medicines.
4. The use in parallel with probenecid Magnikora reduces the effect of both medications.
5. There is no strong interaction between concurrent use of acetylsalicylic acid and magnesium due to the fact that Magnikore has a low content of magnesium.

[5], [6]

Storage conditions

   The storage conditions of Magnikor are as follows:

• In the package in which the medicine was issued.
• At normal temperatures, no more than twenty-five degrees.
• In the sheltered from the children's store.
   

Shelf life

Shelf life of the drug Magnikor compliance with the conditions of proper storage - two years from the date of release.